title: Molecular biotherapy with human monoclonal antibodies.
abstract: Human monoclonal antibodies are theoretically superior to murine monoclonal antibodies for many reasons. However, there are many hurdles in their preparation and clinical use, including the source of B lymphocytes, immortalization techniques, screening methods, scale-up limitations, purification steps, and the problems associated with conjugating to cytotoxic substances. Chimeric mouse/human antibodies are an alternative approach. Optimum clinical utilization will require a better understanding of target antigens and the ability to formulate cocktails.
authors.affiliation: Biotherapeutics, Inc., La Jolla, CA.
authors.forename: M C
authors.initials: MC
authors.lastname: Glassy
authors.forename: R O
authors.initials: RO
authors.lastname: Dillman
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000096:biosynthesis* / Q000302:isolation & purification; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001402:B-Lymphocytes / Q000276:immunology*; D004337:Drug Carriers; D006801:Humans; D051379:Mice; D011993:Recombinant Fusion Proteins / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004337:Drug Carriers; D011993:Recombinant Fusion Proteins